You are here

Home › Guidelines › Statements & Guidelines

Statements & Guidelines

Whether produced alone or in partnership with other organizations, EASD statements and guidelines have significant visibility and substantial impact on health care, particularly when concerning statements on treatment and diagnostic criteria.

The Committee on Clinical Affairs (CCA) is responsible for structuring and overseeing EASD’s activities in the development of formal statements, consensus documents, and other clinical resources that complement the clinical practice guidelines.

The Guidelines Oversight Committee (GOC) is responsible for overseeing the development, implementation, and updating of clinical practice guidelines that adhere to the National Academy of Medicine (NAM) principles and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.

Statements and Guidelines

Evidence-based European recommendations for the dietary management of diabetes by the Diabetes and Nutrition Study Group (DNSG) (2023)

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association (2022)

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022)

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021)

Definition and Interpretation of Remission in Type 2 Diabetes - Consensus report by the Endocrine Society, the European Association for the Study of Diabetes (EASD), Diabetes UK and the American Diabetes Association (ADA) (2021)

Glucose Management for Exercise using Continuous Glucose Monitoring (CGM) and Intermittently Scanned CGM (isCGM) Systems in Type 1 Diabetes – Position Statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA) (2020)

Precision medicine in diabetes. ADA and EASD Consensus Report (2020)

Diabetes digital app technology: benefits, challenges, and recommendations. EASD and ADA Diabetes Technology Working Group Consensus Report (2019)

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. ADA and EASD Cosensus Report (2019)

Management of hyperglycaemia in type 2 diabetes: ADA and EASD Consensus Report (2018)

2016 European Guidelines on CVD Prevention in Clinical Practice (2016)

EASL - EASD - EASO Clinical Practice Guidelines for management of non-alcoholic fatty liver disease (2016)

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015)

Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. A Joint EASD and ADA Statement (2015)

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2013)

ADA/EASD/IDF Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease (2013)

Medical Devices in Diabetes Care: A statement on behalf of the European Association for the Study of Diabetes (2013)

New WHO criteria on use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus (2011)

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009)